Introduction
============

Despite numerous efforts, the search for identification of crucial ligands and receptors being involved in either promotion or inhibition of cell growth, progression and susceptibility to cytotoxic drugs of acute myeloid leukemia (AML) cells is still warranted. Recently, TNF receptor family-related ligands were linked to pathogenesis of hematological malignancies, including AML [@B1], [@B2]. Two of these members, namely BAFF (B cell Activating Factor of the TNF Family) and APRIL (a Proliferation-Inducing Ligand), were shown recently to play crucial role in the development of autoreactive B cells and regulation of cell survival, growth and death [@B3], [@B4]. Interestingly, APRIL and BAFF share two members of TNF superfamily receptors, namely B-cell maturation antigen (BCMA) and transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI), while B-cell activating factor receptor (BAFF-R) appears to be the primary receptor for BAFF only [@B1].

To date, the anti-apoptotic activity of APRIL and BAFF was demonstrated in B-lymphoma, multiple myeloma (MM) and chronic lymphocytic leukemia (B-CLL) [@B5]-[@B7]. However, there were only limited studies on the role of APRIL and BAFF in regulating apoptotic processes in AML. Therefore, in the present study we aimed to determine whether baseline quantification of peripheral blood CD33+ blast cells expressing BAFF, APRIL and their receptors in newly diagnosed AML patients could improve prognosis of treatment response. Additionally, we aimed to analyze whether APRIL and/or BAFF signaling could be involved in regulating leukemic cell sensitivity to chemotherapeutic drugs.

Patients and methods
====================

Peripheral blood from 24 patients with newly diagnosed AML (diagnoses were established following the WHO classification system) was provided by the Department of Hematology, Medical University of Bialystok. The samples were collected upon obtaining a written informed consent pursuant to the rules and tenets of the recently revised Helsinki protocol. Patient\'s median age at the time of sample collection was 55 years and the range was 21-65. Twelve subjects were female and twelve male. Blood counts and flow cytometry were performed in order to confirm the presence of blastic cells, whereas cytogenetic and molecular studies, including FISH (AML1/ETO, CBFß/ MYH11, MLLT3-MLL and frequently mutated genes FLT3-ITD, NPM1, CEBPA) were conducted with a view to determining the risk group, following the WHO recommendation. On this basis, it was established that all the patients involved in the study had a normal karyotype (46XX/46XY) and none of them suffered from mutated core binding factor leukaemia (CEBPA*~mut~*), mutated nucleophosmin (NPM1*~mut~*) or internal tandem duplication of Fms-like tyrosine kinase 3 (FLT3-ITD). AML patients were treated with seven-day induction chemotherapy regimens corresponding to the standard therapy based on the Polish Adult Leukaemia Group: (DAC schedule) [@B8]. After induction, the morphology response was evaluated; twelve patients achieved complete remission (CR) after 1^st^ induction and 12 were non-responders (NR). The detailed characteristic of AML patients and treatment is listed in Table [1](#T1){ref-type="table"}.

Peripheral blood mononuclear cells (PBMCs), from patients before induction therapy, were isolated by using density gradient centrifugation. The cells were counted, cryopreserved and stored in liquid N~2~ for further analysis. In this study we used immunofluorescence staining for multicolor flow cytometry and confocal microscopy, combined bisulfite-restriction analysis (COBRA)**,** quantitative PCR (qPCR) and *in vitro*stimulation. Detailed information about used methods and protocols is shown in [Supplementary materials](#SM1){ref-type="supplementary-material"}.

Statistical analysis was carried out using GraphPad Prism 5 Software. Unpaired Student t test or Wilcoxon matched pair test was used. The Spearman\'s rank correlation coefficient was used to examine correlations. Statistically significant results were identified by a p \<0.05 for all assays performed. The data are presented as mean ± SEM.

Results
=======

AML cells isolated from peripheral blood were used for staining and determination of APRIL, BAFF and their receptor expression. First, we found significant differences (Fig.[1](#F1){ref-type="fig"}A) in frequencies of CD33+ blasts expressing APRIL, BAFF, but not their mean fluorescence intensity (MFI), among groups of patients with varying clinical responses to applied chemotherapy. Non-responders (NR) showed elevated baseline frequencies of APRIL- and BAFF-expressing CD33+ blasts as compared to patients who achieved complete remission (CR) (15.76%±2.48 *vs* 34.16%±6.53, *p*=0.0343 and 40.87%±6.3 *vs* 77.41%±5.34, *p*=0.0021, respectively). Surprisingly, however, there was no difference in plasma levels of APRIL and BAFF between CR and NR patients (data not shown). With regard to APRIL and BAFF receptors, the most striking differences were observed in frequencies of CD33+BCMA+ AML cells. Interestingly, we demonstrated here that the AML patients who did not respond to induction chemotherapy presented barely detectable frequencies (below 1%) of CD33+BCMA+ cells. In contrast, in CR patients we found substantially elevated but still small frequencies of those cells (15.57%±8.64). On the other hand, we found no differences in the frequencies of AML blasts expressing TACI (*p*=0.4555) and BAFF-R (*p*=0.3196). Moreover, we found that patients who further developed CR to induction chemotherapy presented with significantly elevated MFI of BAFF-R and TACI, but not BCMA on AML cells when compared NR (107.4±28.57 *vs* 21,84±7.78, p=0.004; 132.5±32.9 *vs* 30.76±13.67, p=0.0062; 17.66±8.45 *vs* 3.29±0.50 p=0.1213, respectively) (Fig [1](#F1){ref-type="fig"}B).

We next set out to confirm these findings by qPCR analysis of APRIL, BAFF, BCMA, BAFF-R and TACI expression levels (Fig.[1](#F1){ref-type="fig"}C). Surprisingly, we found no differences in BAFF, BAFF-R and TACI expression level in CD33+ AML cells (p\>0.05). In some contrast, we observed a tendency (at a threshold of statistical significance) towards higher expression of APRIL in NR when compared to CR patients (3.284±1.77 *vs* 0.5547±0.17, *p*=0.0745). Importantly, CR patients showed higher BCMA expression when compared to NR (8.16±5.20 *vs* 0.12±0.03, *p*=0.0127 respectively). Next we confirmed membrane BCMA expression on CD33+ AML blasts by immunofluorescence staining (Fig.[1](#F1){ref-type="fig"}D). Again, we demonstrated here that at baseline BCMA expression on AML cells could have been detected only in CR, but not NR patients. Moreover, we correlated APRIL and BAFF expression and BCMA in AML cells. Interestingly, we observed significant negative correlation between the expression of BAFF, but not APRIL, and BCMA in AML cells (*r*=-0.85, *p*=0.00006 and *r*=0.02, *p*=0.93, respectively).

Next, we intended to analyze DNA methylation status of promoter sequences of BCMA gene. Although we did not observe any differences in methylation levels with regard to the type of clinical response to the therapy (data not shown), we found significant negative correlation between the level of methylation of BCMA promoter and the frequencies of CD33+BCMA+ cell (*p*=0.0204, *r*=0.5564).

Finally, in order to directly evaluate the pro-survival effect of APRIL and BAFF on CD33+ cells, we treated the blasts with cytosine arabinoside (AraC), a widely used DNA-damaging drug, either in the presence or absence of recombinant human APRIL and BAFF. As expected, AraC significantly decreased frequencies of live CD33+ AML blasts (Fig.[2](#F2){ref-type="fig"}A). Notably, stimulation with APRIL significantly reduced AraC-related induction of cell death (Fig.[2](#F2){ref-type="fig"}B) in NR but not in CR patients. Additionally, we observed a trend (at a threshold of statistical significance) to increase frequencies of viable cells after BAFF stimulation in presence of AraC (Fig.[2](#F2){ref-type="fig"}C).

Discussion
==========

Our results confirmed the previous observations suggesting a possible involvement of BCMA in regulating apoptosis of AML cells and its usefulness as a potential marker that predict treatment response to induction chemotherapy. It should be noted that, BCMA is now believed to enhance survival of B cells, especially at later stages of their differentiation [@B9]. On the other hand, early studies revealed that BCMA knockout mice did not present with any specific phenotype [@B10]. Subsequent experiments, however, proved that BCMA deficiency led to impaired survival of long-lived bone marrow plasma cells [@B11]. Moreover, a soluble form of BCMA, which inhibited the proliferative activity of APRIL *in vitro*, decreases tumor cell proliferation in nude mice. Additionally, in xenograft models of lung and colon cancer, intratumoral delivery of soluble BCMA was capable of significantly reducing tumor growth in mice, which had been treated with the soluble receptor [@B11]. It is likely, therefore, that BCMA activation cause increased proliferation of AML cells what in turn may be associated with their increased sensitivity to chemotherapeutic drug, including commonly used AraC. On the other hand, soluble BCMA released from BCMA cells may reduce the anti-apoptotic APRIL and BAFF activity [@B12]. This hypothesis, however, did not explain why only a small subset of AML cells show BCMA expression.

To date, several studies indicated that aberrant DNA methylation could also play important role in the progression of numerous human neoplasms, including AML [@B13]. Therefore, we analyzed here DNA methylation status of promoter sequences of BCMA gene. Interestingly, we found, significant negative correlation between the level of methylation of BCMA promoter and the frequencies of CD33+BCMA+ cell, suggesting possible contribution of methylation of BCMA to the resistance of AML cells to the therapy. Additionally, we did not observe any significant relationship between BCMA methylation status and clinical features that may influence on analyzed gene methylation, namely: age, smoking (data not shown). On the other hand, observed negative correlation between BCMA and BAFF expression, suggests regulatory function of the latter. However, the mechanisms of interactions need to be further investigated.

Interestingly, we indicated that APRIL shows protective effect on AML cells and reduces AraC-related induction of cell death. Similarly, Bonci and colleagues showed that neutralization of APRIL circuit resulted in marked induction of cell death in all AML samples, suggesting that APRIL can act as a survival factor for AML cells. Authors demonstrated also that the exogenous expression of APRIL resulted in up-regulation of Bcl-2 in CD34+ cells [@B2]. In contrast, APRIL neutralization resulted in down-regulation of Bcl-2 in primary AML cells [@B2]. Indeed, the intensity of Bcl-2 expression was found to correlate with CR rate, where a higher MFI was associated with a low CR rate after standard intensive chemotherapy [@B14], indicating that APRIL may protect AML from chemotherapeutic drugs through up-regulation of Bcl-2.

In conclusion, we showed here clearly that APRIL and BAFF are important players involved in regulation of apoptosis in CD33+ AML blasts. More importantly, the lack of BCMA expression on AML cells may be useful in prediction of treatment response of myeloid leukemia. However, the exact function of BCMA and regulation of its expression in AML blasts is still unknown and thus requires further investigation.
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![**BCMA in contrast to APRIL and BAFF is overexpressed in CR (complete remission) patients with AML.** (A) Summary of flow cytometry analyses of APRIL, BAFF, BCMA, BAFF-R and TACI expression in CD33+ AML cells in CR (complete remission) and NR (non-responders) patients. (B) Flow cytometry geometric mean fluorescence intensity (MFI) of APRIL, BAFF, BCMA, BAFF-R and TACI in CD33+ AML cells of CR and NR patients. (C) Summary of quantitative PCR analyses of APRIL, BAFF, BCMA, BAFF-R and TACI mRNA expression levels in CD33+ AML cells of CR and NR patients. (C) The differences of immunofluorescence staining for BCMA between CR and NR patients in isolated CD33+ AML cells.](jcav07p1979g001){#F1}

![**April promotes survival of acute myeloid leukemia cells in NR but not in CR patients.** Acute myeloid leukemia cells were treated for 24h with 10µM of cytosine arabinoside (AraC) in the presence or absence of rhAPRIL and rhBAFF. After 24h, the viability of cells was determined by flow cytometry (FACSCalibur, BD) using Propidium Iodide (PI, Becton Dickinson). Graphs are presenting the summary of analyses of: (A) changes in viability of AML cells after incubation in presence or absence of AraC; (B) changes in viability of AML cells after AraC incubation in presence or absence of APRIL in CR (complete remission, left) and NR (non-responders, right) patients; (C) frequencies of viable AML cells after AraC incubation in presence of BAFF in CR (left) and NR (right) patients.](jcav07p1979g002){#F2}

###### 

Characteristics of patients with AML

  Characteristic                                                 AML
  -------------------------------------------------------------- ------------------
  Number of patients                                             24
  Median (range) age, year                                       55 (21-65)
  Median (range) white blood cell count (G/l)                    37.6 (9.9-199.5)
  Median (range) of the blastic cells in peripheral blood        85 (21-97)
  Median (range) of the CD33 expression on blastic cells \[%\]   89 (78-98)
  **AML according to FAB classification**                        22
  AML, minimally differentiated, M0                              7
  AML without maturation, M1                                     6
  AML with maturation, M2                                        5
  Acute myelomonocytic leukemia (AMMoL), M4                      6
  Karyotype                                                      46XX/46XY
  *FLT3-ITD/NMP1~mut~/CEBPA~mut~*                                0/0/0
  CR/NR                                                          12/12

Legends: AML- acute myeloid leukaemia, CR-complete remission, NPM1~mut~ -mutated nucleophosmin, CEBPA~mut~ - mutated core binding factor leukaemia, FLT3-ITD- internal tandem duplication of Fms-like tyrosine kinase 3.
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